Imaging tumors using a new dual-target agent
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
This study is testing a new imaging agent to see if it can help doctors get a clearer picture of tumors in patients with breast, brain, and prostate cancers compared to standard imaging methods.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing) |
| Trial ID | NCT05549024 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of a novel dual-target imaging agent, 68Ga-RM26-RGD, for PET/CT imaging in patients with breast, brain, and prostate cancers. The approach aims to improve tumor visualization by targeting specific receptors that are highly expressed in malignant tissues and their associated neovascularization. By comparing this new agent with conventional imaging methods, the study seeks to enhance diagnostic accuracy for tumors that typically show low uptake in standard imaging. Patients will undergo PET/CT scans using both the new agent and traditional imaging agents to assess the clinical application value of this dual-target approach.
Who should consider this trial
Good fit: Ideal candidates include patients with confirmed or suspected breast, brain, or prostate cancer who can provide informed consent.
Not a fit: Patients who are pregnant, breastfeeding, or have medical conditions that may interfere with study compliance will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic accuracy for certain types of cancer, allowing for better treatment planning.
How similar studies have performed: While conventional imaging methods have been widely used, this dual-target approach is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with confirmed or suspected breast/brain/prostate cancer; * 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week; * signed written consent. Exclusion Criteria: * pregnancy; * breastfeeding; * any medical condition that in the opinion of the investigator may significantly interfere with study compliance.
Where this trial is running
Beijing
- Peking Union Medical College Hospital — Beijing, China (Recruiting)
Study contacts
- Principal investigator: Zhaohui Zhu, MD,PHD — Peking Union Medical College Hospital
- Study coordinator: Zhaohui Zhu, MD,PHD
- Email: 13611093752@163.com
- Phone: 86+13611093752
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.